Osteonecrosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Osteonecrosis – Pipeline Review, H2 2016’, provides an overview of the Osteonecrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteonecrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteonecrosis

The report reviews pipeline therapeutics for Osteonecrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Osteonecrosis therapeutics and enlists all their major and minor projects

The report assesses Osteonecrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Osteonecrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Osteonecrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Osteonecrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bone Therapeutics SA

Enzo Biochem Inc

K-Stemcell Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Osteonecrosis Overview 6

Therapeutics Development 7

Pipeline Products for Osteonecrosis - Overview 7

Osteonecrosis - Therapeutics under Development by Companies 8

Osteonecrosis - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Osteonecrosis - Products under Development by Companies 12

Osteonecrosis - Companies Involved in Therapeutics Development 13

Bone Therapeutics SA 13

Enzo Biochem Inc 14

K-Stemcell Co Ltd 15

Osteonecrosis - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

ALLOB - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

LWnt-3a - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

PREOB - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Osteonecrosis - Dormant Projects 33

Osteonecrosis - Product Development Milestones 34

Featured News & Press Releases 34

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial 34

Jun 08, 2016: Bone Therapeutics demonstrates superiority of PREOB in Phase IIB osteonecrosis study presented at EULAR 34

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study 35

Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB 36

Nov 07, 2013: Bone Therapeutics' pivotal phase III osteonecrosis trial with PREOB hits a new milestone 36

Jan 28, 2013: Bone Therapeutics Raises €1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy 37

Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study 37

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

List of Tables

Number of Products under Development for Osteonecrosis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Osteonecrosis – Pipeline by Bone Therapeutics SA, H2 2016 13

Osteonecrosis – Pipeline by Enzo Biochem Inc, H2 2016 14

Osteonecrosis – Pipeline by K-Stemcell Co Ltd, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Stage and Target, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Osteonecrosis – Dormant Projects, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for Osteonecrosis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports